chrisvoncsefalvay/vaers-outcomes huggingface dataset:
tested positive for Covid after first vaccine dose; flu like symptoms; muscle soreness; achy body; nausea; didn't feel great after that/Felt "hazy"; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (tested positive for Covid after first vaccine dose), FEELING ABNORMAL (didn't feel great after that/Felt "hazy"), INFLUENZA LIKE ILLNESS (flu like symptoms), MYALGIA (muscle soreness) and MYALGIA (achy body) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042E21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Apr-2021, the patient experienced FEELING ABNORMAL (didn't feel great after that/Felt "hazy"). On 01-May-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms), MYALGIA (muscle soreness), MYALGIA (achy body) and NAUSEA (nausea). On 04-May-2021, the patient experienced COVID-19 (tested positive for Covid after first vaccine dose). At the time of the report, COVID-19 (tested positive for Covid after first vaccine dose), FEELING ABNORMAL (didn't feel great after that/Felt "hazy"), INFLUENZA LIKE ILLNESS (flu like symptoms), MYALGIA (muscle soreness), MYALGIA (achy body) and NAUSEA (nausea) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-May-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.  The patient experienced flu like symptoms like muscle soreness, achy body, nausea, fever.  No treatment drugs were reported.   Most recent FOLLOW-UP information incorporated above includes: On 06-May-2021: Follow-up received updated new events. On 06-May-2021: Follow-up received does not contain any significant information.
Information has been received from a physician concerning a female who on 05-MAY-2007 was vaccinated with Gardasil.  The physician reported that on 10-MAY-2007, the patient developed a lesion in the vaginal area.  No other information was reported.  Additional information has been requested.
The day after injection I had a hard knot at the injection site and then the next day the knot became fiery red, warm and painful to touch. Later that same day, I started to have body aches especially in my neck and a nauseous feeling and those symptoms lasted for 2 more days; the hard knot did not recede for another week.
Patient was given MENACTRA as subcutaneous injection rather than an IM injection; no adverse event reported by patient as of 6:00 PM (approximately 45 minutes after vaccine administration).
My calicum level went up very high and I  had trouble with my muscles and was unable to walk for a while.  Spent time in the hospital and was given out patient fluids to get my calcium level down.  Still having trouble with my muscles getting ready to start out  physical therapy .
edema started in her feet and ankles and then moved 3 quarter way to her shin; 4+ pitting edema; This is a spontaneous report from a contactable nurse (patient). A 47-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 17Dec2020 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient reported she received the Covid vaccine on 17Dec2020 and on 25Dec2020 she noticed her shoes were snug and on 26Dec2020 she noticed 4+ pitting edema lasting 3 days. She went and brought some compression stockings and this has helped the edema improve but was still mild. The edema started in her feet and ankles and then moved 3 quarter way to her shin. She would like to know if she should receive second dose of Pfizer vaccine. Outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: The reported information is limited. Based on the close temporal relationship and the description of the events, there is a reasonable possibility that the events are related to BNT162 vaccine. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
This spontaneous report as received from a female patient in her "mid-forties". On 17-FEB-2010 the patient was vaccinated with a dose of M-M-R II (dose, route and lot # not reported). On 17-FEB-2010, the patient experienced fever, chills and body ache for "about 10 days" (recovered approximately on 26-FEB-2010) after administration of the M-M-R II. It was unspecified if the patient sought medical attention. Additional information has been requested.
Covid 19 I tested positive on September 8, 2022 I experienced headcahe, slight fever muscle aches, Fatigue, very bad sore throat,  I took Nyquil and Dayquil
Information has been received from a registered nurse concerning a female who was vaccinated with a dose of GARDASIL (lot#, route and site of administration not reported). Subsequently, the patient experienced syncope episodes after vaccination. Unspecified medical attention was sought. On an unspecified date the patient recovered. This is one of several reports from the same source. Additional information has been requested.
Patient presented 08/10/2005 for Hepatitis B number 2.  At that time during assessment reported after receiving immunization on 06/15/2005 within 1-2 hours developed hives which lasted for several days and still have off and on.
paralyzed from the neck down; Initial information was received on 05-Nov-2020 regarding an unsolicited valid serious social media case from the patient.  This case involves a female patient (age was not reported) who was paralyzed from the neck down (quadriplegia), after she received INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), vaccination(s), family history and concomitant medication were not reported.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and other dosing details were not reported) for prophylactic vaccination.  On an unknown date, the patient was paralyzed from the neck down (quadriplegia), (unknown latency) following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.  The patient was hospitalized for this event on an unknown date for 24 days.   Details of laboratory data were not reported.  It was not reported if the patient received any other corrective treatment.  At the time of reporting, the event outcome was not reported.  Information on the batch number was requested.; Sender's Comments: This poorly documented social media case concerns a female patient of unknown age who had quadriplegia after vaccination with INFLUENZA VACCINE (produced by unknown manufacturer). The time to onset is unknown. Also, the patient's medical condition at the time of vaccination, concomitant medication and lab tests ruling out alternate etiologies were not reported. Based upon the reported information, the role of the vaccine cannot be assessed.
Patient received Moderna vaccine on 1/30/2021, then on 2/27/2021 received Pfizer for 2nd dose. Pt informed of error.
Pt appeared to be having a reaction: sweating, blurred vision, dizziness. Administered EPIPEN. EMTs interviewed him. He was feeling better. It was decided that it was a panic attack, not a rxn to vaccine.
Client complained of dizziness and weakness. Fire Rescue first responded.  Client vitals all within normal limits.  Client showed symptoms of paleness and diaphoresis but recovered by the time of release.  Client was released to home at 11:30am.  No further treatment needed as per Fire Rescue.
he got sleepy; so drowsy; temperature of 99.9; sick for a month; heart felt like it was going to beat out of chest/he felt bad; could hardly hold head up/could not get out of bed; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE, DOWZY, BODY TEMPERATURE ABNORMAL (temperature of 99.9), ILLNESS, and FEELING ABNORMAL (heart felt like it was going to beat out of chest/he felt bad) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029K20A and 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.  Concomitant products included PREDNISONE and METHOTREXATE for an unknown indication.   On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE, DROWSY, BODY TEMPERATURE ABNORMAL (temperature of 99.9), ILLNESS, FEELING ABNORMAL (heart felt like it was going to beat out of chest/he felt bad), and MOBILITY DECREASED (could hardly hold head up/could not get out of bed). At the time of the report, SOMNOLENCE, DROWSY, BODY TEMPERATURE ABNORMAL (temperature of 99.9), ILLNESS (sick for a month), FEELING ABNORMAL (heart felt like it was going to beat out of chest/he felt bad), and MOBILITY DECREASED (could hardly hold head up/could not get out of bed) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available) on 19-Aug-2021, Body temperature 99.9 (High) body temperature elevated.         No treatment medications reported.  Patient has symptoms for a month after third dose, but now he's feeling fine.   Most recent FOLLOW-UP information incorporated above includes on 24-Sep-2021: Significant follow up received on 24 Sep 2021, first and second dosage information added in product tab, outcome of event updated to recovered.
Mother stated child woke up morning after receiving vaccine with hugh temp, but did not take it also c/o headache and stomach cramps.
When I got the shot on March 30th, I felt tired and my arm felt sore. On March 31st (1 day after my first shot), I had a sore throat and was coughing up phlegm. This continued through April 2nd when I started to get a stuffy nose.  April 5th, I got tested for Covid-19 and tested positive and still have the same symptoms.
I began having symptoms by being super sensitive to the air conditioner.  I had cold like symptoms.  I had a runny nose.  I never developed a cough.  I tested positive for COVID-19 but I am not certain what day.  I took cold medicine to help feel better.  By day I was feeling pretty good.  The only lasting symptom I have is when I try to exercise I notice I am having more difficulty breathing than before.
Broke out small rash over left upper eyelid & fever 101 degrees approx. 20 hrs after vaccine.  Next morning awoke with eyelid lid swelling & facial/body hives (urticaria + edema) approx 48 hours of vaccine.  Urticaria & angioedema persisted about 36 hours, improving w/ oral steroid & BENADRYL.
Lumpy area at the injection site; Warm to touch at injection site; Red area at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (Lumpy area at the injection site), VACCINATION SITE WARMTH (Warm to touch at injection site) and VACCINATION SITE ERYTHEMA (Red area at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.).    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Mar-2021, the patient experienced VACCINATION SITE MASS (Lumpy area at the injection site), VACCINATION SITE WARMTH (Warm to touch at injection site) and VACCINATION SITE ERYTHEMA (Red area at the injection site). At the time of the report, VACCINATION SITE MASS (Lumpy area at the injection site), VACCINATION SITE WARMTH (Warm to touch at injection site) and VACCINATION SITE ERYTHEMA (Red area at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.
mild, positive local reactions; Initial information received on 04-Jan-2022 regarding an unsolicited valid non-serious case received from a health professional.  This case involves a patient of unknown demographics who experienced mild, positive local reactions, while receiving vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].     The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date the patient developed mild, positive local reactions (local reaction) (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  It was reported that they needed to skin test a patient to the flu vaccine that they suspected had egg allergy. they used one of our doctors and her nurse as controls who they knew were not allergic to egg. They both had mild, positive local reactions -they were brain storming what we may have done wrong and also were looking into what the differences were between >65 quadrivalent and regular quadrivalent vaccines. The doctor was also asking what the inactive ingredients were.    Action taken with QUADRIVALENT INFLUENZA VACCINE (FLUZONE QUADRIVALENT) was not applicable.  It was not reported if the patient received a corrective treatment for the event (mild, positive local reactions).  At time of reporting, the outcome was Unknown for the event mild, positive local reactions.
Patient reported in his consent form and verbally that he has a prior history of Vasovagal Syncope, but is manageable and definitely wanted to get his Covid 19 Vaccine at the pharmacy. Patient received his vaccine on his right arm, remained seated in his chair. A few seconds later, he decided to lie down on the floor, removed his mask and started taking deep breaths with his eyes closed. About 3 minutes later, his eyes got dilated, skin started flushing red, started with mild seizure like twitching and patient became unresponsive. So I quick put some ice cold water (from his water bottle) on his face, patted his cheek, put an ice pack on his face and neck and while I was asking his father (who was with him) to call 911, the patient regained consciousness and said he was okay.  He continued to put the ice pack on his neck and forehead and in a few minutes the flushing stopped, in about 5 to 8 minutes, patient was able to sit up, lean back against the wall, take a few sips of water and the eat a granola bar. Patient then proceeded to wait in our waiting area for another 15 minutes and then decided to leave , since he was feeling much better.
Pt received H1N1 injection at dr. visit. 5 mins. after administration pt started c/o dizziness, nausea, and shakiness. Pt was told to lay down with feet in air, reported feeling better. Glucola given to pt, also noticed improvement.
Came to office 6/16/2004 for hepatitis vaccine no. 2. Stated 3-4 hours after hepatitis vaccine #1 had "upset stomach" (no vomiting) and weakness. Symptoms resolved in 3-4 hours. Did not seek any medical attention for this. Did not take any medication. Was able to continue working.
This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47-year-old male patient received BNT162b2 (BNT162B2), on 24Feb2022 as dose number unknown, single (Lot number: F35683) at the age of 46 years for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). Concomitant medication(s) included: METFORMIN HCL, start date: Jan2021, stop date: 30Dec2022; AMLODIPINE BESYLATE, start date: Jan2021, stop date: 30Dec2022. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: The patient received Paxlovid for Covid-19 treatment started on 19Dec2022 and stopped on 28Dec2022. No known allergies.
I am having fatigue; muscle soreness; This is a spontaneous report from a contactable consumer (patient). A 48-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number was ER2613),via an unspecified route of administration, administered in Left arm on 27Mar2021 at 13:30 (at the age of 48-years-old) at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination has not been tested for COVID-19. The patient experienced fatigue and muscle soreness on 30Mar2021. The events were reported as non-serious. No treatment was given for the events. The outcome of the events was unknown.  No follow-up attempts are possible. No further information is expected.
Diagnosed with an unspecified autoimmune disorder; fertility issues; This spontaneous report has been received from a nurse practitioner referring a female patient of unknown age. The patient's pertinent medical history, drug reactions, allergies and concomitant medications were not reported.  On an unknown date (reported as years ago), the patient was vaccinated with hpv rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) injection, administered for prophylaxis (strength, specific dosage, vaccination scheme, route of administration, anatomical site of application, lot number and expiration date were not provided)  On an unknown date, the patient was diagnosed with an unspecified autoimmune disorder and fertility issues (female reproductive tract disorder).   The outcome of the events were not provided. The causal relationship between the events and hpv rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) was not reported. The patient believed these issues were caused by hpv rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) .    Upon internal review, the event autoimmune disorder was determined to be medically significant.
This spontaneous report as received from a medical assistant refers to a 17 year old patient of unknown gender. The patient's concurrent conditions, medical history and concomitant medications were not known. On 19-MAY-2014, the patient was vaccinated with the first dose of GARDASIL 9 (lot number J009788 (invalid lot number), expiry 17-MAR-2016), intramuscularly. On 28-JUL-2014, the patient was vaccinated with the second dose (lot number K001500 (invalid lot number), expiry 06-NOV-2016). On 02-DEC-2014, patient was vaccinated with the third dose (lot number K009482 (invalid lot number), expiry 06-MAR-2017) and on 22-NOV-2016, patient was vaccinated with the fourth dose (lot number M023169, expiry 13-JUN-2018). The patient had not experienced an adverse effect. Additional information has been requested.
Patient was  provided with the COVID-19 vaccine outside of the hospital and begain having shortness of breath approximately 15-20 minutes after receiving the vaccination. In route home, the patient could not catch his breath. The patient was found slumped over at home. EMS arrived and the patient received ACLS and ROSC was achieved. Days later, the patient arrested again and passed away on  5/13/21.
TOOK FIRST DOSE ON A FULL STOMACH; This spontaneous case (PVX2019-725) was received from a pharmacist on 26-Mar-2019. It describes a male consumer who "took first dose on a full stomach", while being on Vivotif for an unknown indication.   Case report: The consumer took the first dose of Vivotif on a full stomach and the next dose on empty stomach.  Action taken with Vivotif was not applicable.   The clinical outcome of the event "took first dose on a full stomach" was unknown.  Company's Comment: The causality of the event "took first dose on a full stomach" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "took first dose on a full stomach" was considered as not applicable.
hot; red; infection; scab; This case was reported by a pharmacist via call center representative and described the occurrence of injection site warmth in a 80-year-old female patient who received Herpes zoster (Shingrix) (batch number 3FJ59, expiry date 27th November 2021) for prophylaxis.   On 20th September 2019, the patient received the 2nd dose of Shingrix (intramuscular). On an unknown date, less than 3 months after receiving Shingrix, the patient experienced injection site warmth, injection site erythema, infection and injection site scab. The patient was treated with antibiotics nos (Antibiotics (Brand Names Not Known)). On an unknown date, the outcome of the injection site warmth, injection site erythema and infection were unknown and the outcome of the injection site scab was not recovered/not resolved.   It was unknown if the reporter considered the injection site warmth, injection site erythema, infection and injection site scab to be related to Shingrix.  Additional details were received as follows: The reporter stated that the patient received the 2nd dose of Shingrix and after the injection, the injection site became very red and hot.  The patient was infected and was prescribed antibiotics. The reporter stated that the site scabbed over and the scab were there till time of reporting. The reporter stated that the patient will sometimes bump into something and reaggrevate the site.
Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Severe, Systemic: Chest Tightness / Heaviness / Pain-Mild, Systemic: Dizziness / Lightheadness-Medium, Systemic: Headache-Severe
Apparent local reaction: oblong red spot on skin near injection site, soreness that lasted 4+ days, itchiness on 4th day, swelling on arm below injection site. This reaction did not occur after first 2 Moderna shots. Please note, lot number is illegible on card, different from lot number on Vaccine administration record, which contains several errors.
2 weeks after receiving vaccine child woke up with rash foster mother describes it as fine, measles, red rash all over. It progressively got worse & by that night child has covered with rash. Never had fever or any other symptom - only rash. Foster mother took child to convenient care Rx evaluation. Doctor told foster mother it was a reaction to MMR & would go away on its own & to keep out of daycare until 24 hours fever free. 6-17-12 - onset of symptoms. 6-19-12 - took to doctor. 6-21-12 - clearing up (rash).
p/vax broke out w/rash, palms, feet, leg, abd;legs & arms swollen;saw MD;tx w/antihistamine, ATB;no improvement saw MD again;tx mega pak ATB;no improvement now red & stretched;tongue sensitive, finger tips sore;
PATIENT CALLED ON MONDAY 05/17/21 AND STATED THEY HAD A RASH ON TRUNK AND BACK AND A FEVER OF 101.8 ADVISED TO TAKE SOME TYLENOL AND BENADRYL AND NOTIFY THEIR PHYSICIAN
Pt developed urticaria and swelling of left side within hours of getting VARIVAX vaccine.